{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,31]],"date-time":"2026-03-31T10:18:20Z","timestamp":1774952300048,"version":"3.50.1"},"reference-count":46,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2018,8,3]],"date-time":"2018-08-03T00:00:00Z","timestamp":1533254400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Harm Reduct J"],"published-print":{"date-parts":[[2018,12]]},"DOI":"10.1186\/s12954-018-0246-6","type":"journal-article","created":{"date-parts":[[2018,8,3]],"date-time":"2018-08-03T10:25:21Z","timestamp":1533291921000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["A policy analysis exploring hepatitis C risk, prevention, testing, treatment and reinfection within Australia\u2019s prisons"],"prefix":"10.1186","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8533-2957","authenticated-orcid":false,"given":"Lise","family":"Lafferty","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"T. Cameron","family":"Wild","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jake","family":"Rance","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carla","family":"Treloar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2018,8,3]]},"reference":[{"key":"246_CR1","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1016\/S2468-1253(16)30181-9","volume":"2","author":"S Blach","year":"2017","unstructured":"Blach S, Zeuzem S, Manns M, Altraif I, Duberg A-S, Muljono DH, Waked I, Alavian SM, Lee M-H, Negro F, et al. Global prevalence and genotype distribution of hepatitis C virus infection in 2015: a modelling study. Lancet Gastroenterol Hepatol. 2017;2:161\u201376.","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"246_CR2","doi-asserted-by":"publisher","first-page":"558","DOI":"10.1016\/S1473-3099(05)70216-4","volume":"5","author":"CW Shepard","year":"2005","unstructured":"Shepard CW, Finelli L, Alter MJ. Global epidemiology of hepatitis C virus infection. Lancet Infect Dis. 2005;5:558\u201367.","journal-title":"Lancet Infect Dis"},{"key":"246_CR3","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1038\/nrgastro.2013.107","volume":"10","author":"B Hajarizadeh","year":"2013","unstructured":"Hajarizadeh B, Grebely J, Dore GJ. Epidemiology and natural history of HCV infection. Nat Rev Gastroenterol Hepatol. 2013;10:553\u201362.","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"246_CR4","doi-asserted-by":"publisher","first-page":"1215","DOI":"10.1002\/hep.26387","volume":"58","author":"S Larney","year":"2013","unstructured":"Larney S, Kopinski H, Beckwith CG, Zaller ND, Jarlais DD, Hagan H, Rich JD, van den Bergh BJ, Degenhardt L. Incidence and prevalence of hepatitis C in prisons and other closed settings: results of a systematic review and meta-analysis. Hepatology. 2013;58:1215\u201324.","journal-title":"Hepatology"},{"key":"246_CR5","doi-asserted-by":"publisher","first-page":"1089","DOI":"10.1016\/S0140-6736(16)30466-4","volume":"388","author":"K Dolan","year":"2016","unstructured":"Dolan K, Wirtz AL, Moazen B, Ndeffo-mbah M, Galvani A, Kinner SA, Courtney R, McKee M, Amon JJ, Maher L, et al. Global burden of HIV, viral hepatitis, and tuberculosis in prisoners and detainees. Lancet. 2016;388:1089\u2013102.","journal-title":"Lancet"},{"key":"246_CR6","unstructured":"Butler T, Simpson M. National Prison Entrants\u2019 Blood-borne Virus Survey report 2004, 2007, 2010, 2013, and 2016. Sydney: The Kirby Institute (UNSW Sydney); 2017."},{"key":"246_CR7","doi-asserted-by":"publisher","first-page":"1350","DOI":"10.1136\/gut.2005.076646","volume":"55","author":"MP Manns","year":"2006","unstructured":"Manns MP, Wedemeyer H, Cornberg M. Treating viral hepatitis C: efficacy, side effects, and complications. Gut. 2006;55:1350\u20139.","journal-title":"Gut"},{"key":"246_CR8","doi-asserted-by":"publisher","first-page":"022","DOI":"10.1055\/s-0034-1371007","volume":"34","author":"J-M Pawlotsky","year":"2014","unstructured":"Pawlotsky J-M. New hepatitis C virus (HCV) drugs and the hope for a cure: concepts in anti-HCV drug development. Semin Liver Dis. 2014;34:022\u20139.","journal-title":"Semin Liver Dis"},{"key":"246_CR9","doi-asserted-by":"publisher","first-page":"1829","DOI":"10.1093\/cid\/civ197","volume":"60","author":"GJ Dore","year":"2015","unstructured":"Dore GJ, Feld JJ. Hepatitis C virus therapeutic development: in pursuit of \u201cPerfectovir\u201d. Clin Infect Dis. 2015;60:1829\u201336.","journal-title":"Clin Infect Dis"},{"key":"246_CR10","doi-asserted-by":"publisher","first-page":"1576","DOI":"10.1056\/NEJMp1400986","volume":"370","author":"RT Chung","year":"2014","unstructured":"Chung RT, Baumert TF. Curing chronic hepatitis C\u2013\u2013the arc of a medical triumph. N Engl J Med. 2014;370:1576\u20138.","journal-title":"N Engl J Med"},{"key":"246_CR11","doi-asserted-by":"publisher","first-page":"1014","DOI":"10.1093\/cid\/cit377","volume":"57","author":"J Grebely","year":"2013","unstructured":"Grebely J, Matthews GV, Lloyd AR, Dore GJ. Elimination of hepatitis C virus infection among people who inject drugs through treatment as prevention: feasibility and future requirements. Clin Infect Dis. 2013;57:1014\u201320.","journal-title":"Clin Infect Dis"},{"key":"246_CR12","doi-asserted-by":"publisher","first-page":"576","DOI":"10.1097\/QCO.0000000000000216","volume":"28","author":"M Hickman","year":"2015","unstructured":"Hickman M, De Angelis D, Vickerman P, Hutchinson S, Martin NK. Hepatitis C virus treatment as prevention in people who inject drugs: testing the evidence. Curr Opin Infect Dis. 2015;28:576\u201382.","journal-title":"Curr Opin Infect Dis"},{"key":"246_CR13","first-page":"CD012021","volume":"9","author":"L Platt","year":"2017","unstructured":"Platt L, Minozzi S, Reed J, Vickerman P, Hagan H, French C, Jordan A, Degenhardt L, Hope V, Hutchinson S, et al. Needle syringe programmes and opioid substitution therapy for preventing hepatitis C transmission in people who inject drugs. Cochrane Database Syst Rev. 2017;9:CD012021.","journal-title":"Cochrane Database Syst Rev"},{"key":"246_CR14","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1016\/S2468-1253(16)30075-9","volume":"1","author":"B Hajarizadeh","year":"2016","unstructured":"Hajarizadeh B, Grebely J, Martinello M, Matthews GV, Lloyd AR, Dore GJ. Hepatitis C treatment as prevention: evidence, feasibility, and challenges. Lancet Gastroenterol Hepatol. 2016;1:317\u201327.","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"246_CR15","volume-title":"Turnbull govt invests over $1B to cure hep C","author":"Ministry of Health","year":"2015","unstructured":"Ministry of Health. Turnbull govt invests over $1B to cure hep C. Canberra: The Hon Sussan Ley MP, Minister for Health; 2015."},{"key":"246_CR16","doi-asserted-by":"publisher","first-page":"215","DOI":"10.7326\/M15-0406","volume":"163","author":"S Barua","year":"2015","unstructured":"Barua S, Greenwald R, Grebely J, Dore GJ, Swan T, Taylor LE. Restrictions for Medicaid reimbursement of sofosbuvir for the treatment of hepatitis c virus infection in the United States. Ann Intern Med. 2015;163:215\u201323.","journal-title":"Ann Intern Med"},{"key":"246_CR17","doi-asserted-by":"publisher","first-page":"E605","DOI":"10.9778\/cmajo.20160008","volume":"4","author":"AD Marshall","year":"2016","unstructured":"Marshall AD, Saeed S, Barrett L, Cooper CL, Treloar C, Bruneau J, Feld JJ, Gallagher L, Klein MB, Krajden M, et al. Restrictions for reimbursement of direct-acting antiviral treatment for hepatitis C virus infection in Canada: a descriptive study. CMAJ Open. 2016;4:E605\u201314.","journal-title":"CMAJ Open"},{"key":"246_CR18","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1016\/S2468-1253(17)30284-4","volume":"3","author":"AD Marshall","year":"2018","unstructured":"Marshall AD, Cunningham EB, Nielsen S, Aghemo A, Alho H, Backmund M, Bruggmann P, Dalgard O, Seguin-Devaux C, Flisiak R, et al. Restrictions for reimbursement of interferon-free direct-acting antiviral drugs for HCV infection in Europe. Lancet Gastroenterol Hepatol. 2018;3:125\u201333.","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"246_CR19","doi-asserted-by":"publisher","first-page":"374","DOI":"10.1097\/COH.0000000000000179","volume":"10","author":"NK Martin","year":"2015","unstructured":"Martin NK, Vickerman P, Dore GJ, Hickman M. The hepatitis C virus epidemics in key populations (including people who inject drugs, prisoners and MSM): the use of direct-acting antivirals as treatment for prevention. Curr Opin HIV AIDS. 2015;10:374\u201380.","journal-title":"Curr Opin HIV AIDS"},{"key":"246_CR20","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1108\/IJPH-08-2015-0025","volume":"12","author":"MM Mina","year":"2016","unstructured":"Mina MM, Herawati L, Butler T, Lloyd A. Hepatitis C in Australian prisons: a national needs assessment. Int J Prison Health. 2016;12:3\u201316.","journal-title":"Int J Prison Health"},{"key":"246_CR21","volume-title":"Evidence and Evaluation Guidance Series, Population and Public Health Division","author":"A Milat","year":"2014","unstructured":"Milat A, Newson R, King L. Increasing the scale of population health interventions: a guide. In: Evidence and Evaluation Guidance Series, Population and Public Health Division. NSW Ministry of Health: Sydney; 2014."},{"key":"246_CR22","volume-title":"Prisoner health services in Australia. 14 Aug 2014 edition","author":"AIHW","year":"2014","unstructured":"AIHW. Prisoner health services in Australia. 14 Aug 2014 edition. Australian Institute of Health & Welfare: Canberra; 2014."},{"key":"246_CR23","volume-title":"Regulating hepatitis C: rights and duties, preventing hepatitis C transmission in Australian adult correctional settings","author":"J Wallace","year":"2010","unstructured":"Wallace J, Pitts M, McNally S, Malkin I, Temple-Smith M, Smith A, Levy M. Regulating hepatitis C: rights and duties, preventing hepatitis C transmission in Australian adult correctional settings. Melbourne: Australian Research Centre in Sex, Health and Society, La Trobe University; 2010."},{"key":"246_CR24","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1111\/dar.12374","volume":"35","author":"A Ritter","year":"2016","unstructured":"Ritter A, Berends L. Twenty years of (non)reform in Victorian alcohol and other drug treatment policy. Drug Alcohol Rev. 2016;35:250\u20134.","journal-title":"Drug Alcohol Rev"},{"key":"246_CR25","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1186\/s12954-017-0177-7","volume":"14","author":"E Hyshka","year":"2017","unstructured":"Hyshka E, Anderson-Baron J, Karekezi K, Belle-Isle L, Elliott R, Pauly B, Strike C, Asbridge M, Dell C, McBride K, et al. Harm reduction in name, but not substance: a comparative analysis of current Canadian provincial and territorial policy frameworks. Harm Reduct J. 2017;14:50.","journal-title":"Harm Reduct J"},{"key":"246_CR26","unstructured":"Victoria Health and Human Services. Victorian hepatitis C strategy 2016\u20132020. Melbourne: Victoria State Government; 2016."},{"key":"246_CR27","unstructured":"Queensland Health. Queensland alcohol and other drugs action plan 2015\u20132017: thriving communities. Brisbane: Queensland Government; 2015."},{"key":"246_CR28","unstructured":"South Australia Department of Health and Ageing. South Australian Hepatitis C Implementation and Evaluation Plan 2015\u20132016. Adelaide: Government of South Australia; 2015."},{"key":"246_CR29","unstructured":"South Australia Department for Correctional Services and South Australia Department for Health and Ageing. South Australian Prisoner Blood Borne Virus Prevention Action Plan 2017\u20132020. Adelaide: Government of South Australia; 2017."},{"key":"246_CR30","unstructured":"Corrections Victoria. Corrections alcohol and drug strategy 2015. Melbourne: Victoria State Government; 2015."},{"key":"246_CR31","unstructured":"Western Australia Department of Health. Western Australia hepatitis C strategy 2015\u20132018. Perth: Government of Western Australia; 2015."},{"key":"246_CR32","unstructured":"Western Australia Department of Health. Hepatitis C virus model of care. Perth: Government of Western Australia; 2009."},{"key":"246_CR33","unstructured":"NSW Ministry of Health. NSW hepatitis C strategy 2014\u20132020. Sydney: NSW Ministry of Health; 2014."},{"key":"246_CR34","unstructured":"ACT Government. Strategic framework for the management of blood-borne viruses in the Alexander Maconochie Centre 2013\u20132017. Canberra: ACT Government; 2013."},{"key":"246_CR35","unstructured":"SA Prison Health Service. SA Prison Health Service Model of Care. Adelaide: Government of South Australia; 2016."},{"key":"246_CR36","unstructured":"ACT Health. ACT statement of priorities 2016\u20132020: hepatitis B, hepatitis C, HIV, and sexually transmissable infections. Canberra: ACT Government; 2016."},{"key":"246_CR37","unstructured":"ACT Government. Corrections management (infectious diseases) policy 2014 (no 1). Canberra: ACT Government; 2014."},{"key":"246_CR38","unstructured":"Victoria Office of the Correctional Services Commissioner. Identified drug user program: key policies and procedures. Melbourne: Victoria State Government; 2002."},{"key":"246_CR39","doi-asserted-by":"publisher","first-page":"1259","DOI":"10.1001\/jama.2012.374","volume":"307","author":"AC Spaulding","year":"2012","unstructured":"Spaulding AC, Thomas DL. Screening for HCV infection in jails. JAMA. 2012;307:1259\u201360.","journal-title":"JAMA"},{"key":"246_CR40","doi-asserted-by":"publisher","first-page":"1078","DOI":"10.1093\/cid\/cis1202","volume":"56","author":"AR Lloyd","year":"2013","unstructured":"Lloyd AR, Clegg J, Lange J, Stevenson A, Post JJ, Lloyd D, Rudge G, Boonwaat L, Forrest G, Douglas J, Monkley D. Safety and effectiveness of a nurse-led outreach program for assessment and treatment of chronic hepatitis C in the custodial setting. Clin Infect Dis. 2013;56:1078\u201384.","journal-title":"Clin Infect Dis"},{"key":"246_CR41","doi-asserted-by":"publisher","first-page":"319","DOI":"10.5694\/mja15.00523","volume":"203","author":"M Stoov\u00e9","year":"2015","unstructured":"Stoov\u00e9 M, Treloar CJ, Maher L, Tyrrell H, Wallace J. Salvaging a prison needle and syringe program trial in Australia requires leadership and respect for evidence. Med J Aust. 2015;203:319\u201320.","journal-title":"Med J Aust"},{"key":"246_CR42","doi-asserted-by":"publisher","first-page":"958","DOI":"10.1016\/j.drugpo.2015.05.006","volume":"26","author":"M Hellard","year":"2015","unstructured":"Hellard M, McBryde E, Sacks Davis R, Rolls DA, Higgs P, Aitken C, Thompson A, Doyle J, Pattison P, Robins G. Hepatitis C transmission and treatment as prevention &#x2013: the role of the injecting network. Int J Drug Policy. 2015;26:958\u201362.","journal-title":"Int J Drug Policy"},{"key":"246_CR43","doi-asserted-by":"crossref","unstructured":"Cunningham EB, Hajarizadeh B, Bretana NA, Amin J, Betz-Stablein B, Dore GJ, Luciani F, Teutsch S, Dolan K, Lloyd AR, et al. Ongoing incident hepatitis C virus infection among people with a history of injecting drug use in an Australian prison setting, 2005\u20132014: the HITS-p study. J Viral Hepat. 2017;24:733\u201341.","DOI":"10.1111\/jvh.12701"},{"key":"246_CR44","doi-asserted-by":"publisher","first-page":"765","DOI":"10.3201\/eid2105.141832","volume":"21","author":"N Breta\u00f1a","year":"2015","unstructured":"Breta\u00f1a N, Boelen L, Bull R, Teutsch S, White P, Lloyd A, Luciani F. Transmission of hepatitis C virus among prisoners, Australia, 2005\u20132012. Emerg Infect Dis. 2015;21:765\u201374.","journal-title":"Emerg Infect Dis"},{"key":"246_CR45","doi-asserted-by":"publisher","first-page":"1115","DOI":"10.1016\/S0140-6736(16)30769-3","volume":"388","author":"A Kamarulzaman","year":"2016","unstructured":"Kamarulzaman A, Reid SE, Schwitters A, Wiessing L, El-Bassel N, Dolan K, Moazen B, Wirtz AL, Verster A, Altice FL. Prevention of transmission of HIV, hepatitis B virus, hepatitis C virus, and tuberculosis in prisoners. Lancet. 2016;388:1115\u201326.","journal-title":"Lancet"},{"key":"246_CR46","unstructured":"Dore GJ. Eliminating hepatitis C over the next decade. Sydney: UNSW Australia; 2016."}],"container-title":["Harm Reduction Journal"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12954-018-0246-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12954-018-0246-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12954-018-0246-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,8,2]],"date-time":"2019-08-02T19:09:52Z","timestamp":1564772992000},"score":1,"resource":{"primary":{"URL":"https:\/\/harmreductionjournal.biomedcentral.com\/articles\/10.1186\/s12954-018-0246-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,8,3]]},"references-count":46,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2018,12]]}},"alternative-id":["246"],"URL":"https:\/\/doi.org\/10.1186\/s12954-018-0246-6","relation":{},"ISSN":["1477-7517"],"issn-type":[{"value":"1477-7517","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,8,3]]},"assertion":[{"value":"26 March 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 July 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 August 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Not applicable.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Publisher\u2019s Note"}}],"article-number":"39"}}